Clinical Trials Logo

Clinical Trial Summary

The main objective of this study is to further evaluate the safety and efficacy of palovarotene in adult and paediatric participants with FOP. The aim of the study is also to ensure treatment continuity to participants who have completed one of the parent studies (Study PVO-1A-301, Study PVO-1A-202 and Study PVO-1A-204) and who, in the investigator's judgement, may benefit from palovarotene therapy.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

  • Fibrodysplasia Ossificans Progressiva (FOP)

NCT number NCT05027802
Study type Interventional
Source Ipsen
Contact Ipsen Recruitment Enquiries
Phone see email
Email [email protected]
Status Not yet recruiting
Phase Phase 3
Start date November 15, 2021
Completion date November 11, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT02745158 - The Fibrodysplasia Ossificans Progressiva (FOP) Connection Registry N/A